AXIL Brands (AXIL) reported fiscal first-quarter earnings of $0.05 per diluted share, up 25.0% from a year ago, on revenue of $6.09 million, down 11.2%. There was no published consensus or Earnings Whisper to measure against. That leaves the quarter to be judged on its own internals, and those internals are less flattering than the EPS growth suggests. The headline profit came from a one-time customs duty refund. The real story is the XCOR II launch, which did not touch first-quarter revenue at all. Q1 was a transition quarter, and the investment case now depends on how quickly the new product's order book becomes recognized sales.
The quality of the beat over last year deserves scrutiny. Gross margin jumped to 82.6% from 67.6%, but that included a non-recurring $0.55 million IEEPA customs refund booked as a reduction to cost of revenues. Management put underlying gross margin at 73.6%, which it described as in line with history. The refund was larger than the quarter's entire $437,000 of operating income. According to the call, adjusted EBITDA excluding the refund was only about $276,000, against the reported $827,000 and roughly $1.7 million in the fourth quarter. Operating expenses climbed to 75.4% of revenue from 61.6% a year ago. The drivers were about $360,000 of XCOR II advertising, a new $460,000 research and development line that was absent last year, and a $138,000 non-cash charge tied to Reviv3 equity. That reverses the operating-leverage narrative AXIL built in fiscal 2026, when opex fell to 59.7% of revenue. Management says all refund claims have now been collected, so this tailwind will not recur.
Revenue growth decelerated sharply, from +48.9% in the fourth quarter to an 11.2% decline. Sequentially, sales fell from $8.6 million. The weakness was concentrated in retail and wholesale, which fell 29.2% to $2.2 million because a prior-year big-box order did not repeat. First-generation XCOR sales also slowed ahead of the transition. Direct-to-consumer hearing revenue was the steadier piece, down less than 1%. That suggests end demand held up better than the consolidated number implies. It also highlights how lumpy retail order timing continues to drive AXIL's quarterly results.
The balance sheet improved meaningfully. Operating cash flow was $3.8 million, compared with $739,000 used a year earlier, and cash reached a record $7.9 million with no debt. Investors should recognize where that cash came from. Receivables fell from $4.7 million to $1.3 million as strong fourth-quarter sales were collected. That is a working-capital release, not a new run rate of cash generation.
The call preserved a credible near-term growth story built on XCOR II. The product became available September 15. Orders exceeded $2.8 million by August 26 and $3.6 million by September 30, across retail, distribution, and direct-to-consumer, and the CEO called it the strongest early demand for any AXIL product. Management said the majority of that backlog had been fulfilled by quarter-end September, which points to second-quarter recognition. Tone was noticeably more constructive than last quarter:
- The CEO said management was more constructive than at any point.
- He reiterated fiscal 2027 top- and bottom-line growth, weighted from the second quarter onward.
- He called $100 million in sales achievable without acquisitions.
- The CFO framed gross margin at 67% to 74% through fiscal 2027. That is a firmer stance than his fourth-quarter warning that channel mix would pressure margins.
On Reviv3, AXIL brought in three strategic partners for roughly 25% of the subsidiary, kept control, and spent no cash. Distributor and retailer onboarding could begin as early as next quarter.
Bears have legitimate ammunition. There is still no formal quarterly guidance. Orders are not revenue, and the company itself flags cancellation and return risk. The $100 million aspiration sits very far from a $6 million quarter. Market context is thin for this report. Shares opened at $6.71 after the prior release, modestly above a 200-day moving average now at $6.56. No current price or sentiment reading was available to show how investors have positioned into or after the print.
The bottom line is that AXIL's 25% EPS growth flatters a quarter in which revenue fell, operating costs outran sales, and core profitability was thin without a refund that will not repeat. What changed is the forward setup. A $3.6 million XCOR II order book, record debt-free cash, and a firmer margin framework give management a tangible basis for its second-quarter rebound claim. The next report has to show those orders converting into revenue growth and restored operating leverage.